148 related articles for article (PubMed ID: 20373246)
21. Vorapaxar for the reduction of atherothrombotic events.
Diaz-Ricart M; Escolar G
Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
[TBL] [Abstract][Full Text] [Related]
22. PepTalk--CHI's Ninth Annual Meeting--Engineering Protein & Peptide Therapeutics: Peptides.
Craik D
IDrugs; 2010 Mar; 13(3):156-8. PubMed ID: 20191429
[TBL] [Abstract][Full Text] [Related]
23. High-Content Analysis 2005--CHI's Second Annual Conference. 25-28 January 2005, San Francisco, CA, USA.
Rausch O
IDrugs; 2005 Mar; 8(3):197-9. PubMed ID: 15772886
[No Abstract] [Full Text] [Related]
24. HIV co-receptor inhibitors as novel class of anti-HIV drugs.
Schols D
Antiviral Res; 2006 Sep; 71(2-3):216-26. PubMed ID: 16753228
[TBL] [Abstract][Full Text] [Related]
25. Proteomics--CHI's Fourth Annual Conference. 22-23 June 2000, San Francisco, CA, USA.
Rapundalo S
IDrugs; 2000 Oct; 3(10):1171-5. PubMed ID: 16049836
[No Abstract] [Full Text] [Related]
26. Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
[TBL] [Abstract][Full Text] [Related]
27. The potential use of selective 5-HT2C agonists in treating obesity.
Smith BM; Thomsen WJ; Grottick AJ
Expert Opin Investig Drugs; 2006 Mar; 15(3):257-66. PubMed ID: 16503763
[TBL] [Abstract][Full Text] [Related]
28. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
[TBL] [Abstract][Full Text] [Related]
29. Drug management of obesity--efficacy versus safety.
Astrup A
N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205
[No Abstract] [Full Text] [Related]
30. Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
Leonardi S; Tricoci P; Becker RC
Adv Cardiol; 2012; 47():87-99. PubMed ID: 22906905
[TBL] [Abstract][Full Text] [Related]
31. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.
Hoveyda HR; Marsault E; Gagnon R; Mathieu AP; Vézina M; Landry A; Wang Z; Benakli K; Beaubien S; Saint-Louis C; Brassard M; Pinault JF; Ouellet L; Bhat S; Ramaseshan M; Peng X; Foucher L; Beauchemin S; Bhérer P; Veber DF; Peterson ML; Fraser GL
J Med Chem; 2011 Dec; 54(24):8305-20. PubMed ID: 22106937
[TBL] [Abstract][Full Text] [Related]
32. [Potential of proteinase-activated receptors as a novel target for treatment of pulmonary hypertension].
Hirano K
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):182-6. PubMed ID: 24717606
[No Abstract] [Full Text] [Related]
33. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
Bridger GJ; Skerlj RT; Padmanabhan S; Martellucci SA; Henson GW; Struyf S; Witvrouw M; Schols D; De Clercq E
J Med Chem; 1999 Sep; 42(19):3971-81. PubMed ID: 10508445
[TBL] [Abstract][Full Text] [Related]
34. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
French SL; Arthur JF; Tran HA; Hamilton JR
Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
[TBL] [Abstract][Full Text] [Related]
35. Investigational therapies in the treatment of obesity.
Mancini MC; Halpern A
Expert Opin Investig Drugs; 2006 Aug; 15(8):897-915. PubMed ID: 16859393
[TBL] [Abstract][Full Text] [Related]
36. The bicyclam AMD3100 story.
De Clercq E
Nat Rev Drug Discov; 2003 Jul; 2(7):581-7. PubMed ID: 12815382
[TBL] [Abstract][Full Text] [Related]
37. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
Ungar L; Rodriguez F; Mahaffey KW
Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
[TBL] [Abstract][Full Text] [Related]
38. American Chemical Society--238th National Meeting & Exposition. Novel small molecule therapeutics. 16-20 August 2009, Washington DC, USA.
Rotella DP
IDrugs; 2009 Oct; 12(10):612-3. PubMed ID: 19790006
[TBL] [Abstract][Full Text] [Related]
39. The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin.
Pustovit RV; Callaghan B; Kosari S; Rivera LR; Thomas H; Brock JA; Furness JB
Neurogastroenterol Motil; 2014 Feb; 26(2):264-71. PubMed ID: 24304447
[TBL] [Abstract][Full Text] [Related]
40. 28th Annual JPMorgan Healthcare Conference--Forest Laboratories and Icagen.
Gale S; Croasdell G
IDrugs; 2010 Mar; 13(3):145-8. PubMed ID: 20191426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
